EpiCypher®, a pioneer in epigenomic research and technology, announces the launch of CUTANA® Fiber-seq, a groundbreaking multiomic genomics platform that captures both genomic and epigenomic information in a single long-read sequencing assay. This first-of-its-kind technology delivers unprecedented resolution of DNA sequence and chromatin features along individual DNA molecules, opening an entirely new dimension of genome biology with wide-ranging applications in basic research, drug discovery, and clinical medicine.

The Fiber-seq workflow begins with nuclei treated with the Hia5 methyltransferase, which deposits 6mA marks at regions of accessible DNA. Chromatin fibers are then extracted and subjected to long-read sequencing (PacBio® or Oxford Nanopore Technologies®), where both the Hia5-incorporated 6mA modifications and the underlying DNA sequence are directly detected. This generates a single-molecule, multiomic readout that integrates genetic information, endogenous DNA methylation, and chromatin accessibility across long, continuous DNA molecules. Unlike conventional ATAC-seq, Fiber-seq provides base-pair resolution of transcription factor footprints along individual DNA fibers, enabling precise detection of protein–DNA interactions that regulate gene expression. 

“Fiber-seq gives an unprecedented view of the genome - not just the sequence, but the epigenomic states of individual DNA molecules,” said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. “This offers a new lens into biology and disease, with transformative implications for fundamental research and translational science.”

As an initial commercial offering, EpiCypher has launched the CUTANA® Hia5 for Fiber-seq, the key enzyme used in the optimized Fiber-seq protocol. This enables researchers to rapidly adopt and deploy the platform in their own labs. EpiCypher also now offers Early Access CUTANA® Fiber-seq Assay Services, designed to accelerate access to this cutting-edge technology. These services extend the success of EpiCypher’s industry-leading automated CUTANA® CUT&RUN platform, offering a powerful suite of tools to study gene regulation at unparalleled resolution.

Fiber-seq technology addresses critical challenges across diverse fields:

• Basic & Translational Research: Map genetic and epigenetic landscapes on individual molecules to uncover complex mechanisms of genome regulation.
• Drug Discovery & Development: Identify and validate novel therapeutic targets by resolving chromatin states and DNA modifications at high resolution.
• Clinical Research & Diagnostics: Enable precision medicine applications, including the diagnosis of rare diseases, as demonstrated in a landmark Nature Genetics publication* showcasing Fiber-seq’s power in uncovering genetic drivers of rare disorders.

“We are thrilled to bring epigenomics to the cutting-edge of long read sequencing technology,” added Martis Cowles, Chief Business Officer at EpiCypher. “CUTANA® Fiber-seq is the gateway to a powerful new era of single-molecule multiomics that will advance research and precision medicine in ways that were simply not possible using current short read workflows.”

*Vollger, M.R., Korlach, J., Eldred, K.C. et al. Synchronized long-read genome, methylome, epigenome and transcriptome profiling resolve a Mendelian condition. Nat Genet 57, 469–479 (2025). https://doi.org/10.1038/s41588-024-02067-0

About EpiCypher Inc.

EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. The company is at the forefront of chromatin mapping technologies with the CUTANA® platform for ultra-sensitive genomic profiling assays, including CUT&RUN and CUT&Tag, and now, the groundbreaking Fiber-seq platform. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services.

EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide.
________________________________________